Direct answers grouped by company programs, scientific evidence and open questions, clinical study status, and institutional investor access.
Sub-perceptual describes the design goal for XYCO-02. The low-dose oral regimen is formulated to stay below the threshold of noticeable psychedelic effects. Whether participants with mild PTSD can distinguish XYCO-02 from placebo during repeated dosing remains an open question.
01 · Category One
Xycota Biosciences is a preclinical central-nervous-system (CNS) biotechnology company developing two investigational candidates: XYCO-02, a sub-perceptual oral psilocybin capsule designed for a proposed at-home study in mild PTSD, and XYCO-01, a preclinical exosome-encapsulated psilocin candidate for frontotemporal dementia (FTD).
XYCO-02 is Xycota's lead investigational candidate for mild PTSD. It uses a sub-perceptual oral dose of psilocybin, formulated to minimize noticeable psychedelic effects and intended to investigate whether the BDNF/TrkB signaling pathway studied in animal models can support symptom improvement in a proposed 28-day at-home study. XYCO-02 is preclinical and not approved by any regulatory authority.
XYCO-01 is Xycota's preclinical follow-on candidate for frontotemporal dementia (FTD), a rare neurodegenerative disease. It is designed to use engineered, cell-derived exosomes to carry psilocin across the blood-brain barrier. An FDA Orphan Drug Designation application has been filed, and preclinical animal efficacy studies are gated behind XYCO-02's clinical initiation to preserve capital efficiency.
Conventional psychedelic-assisted therapy uses high, perception-altering doses (around 25 mg) delivered in supervised sessions lasting 6 to 8 hours at specialized clinics (Goodwin et al., NEJM 2022). XYCO-02 instead proposes a sub-perceptual oral capsule designed for a 28-day at-home study in adults with mild PTSD.
Xycota is led by Dr. Marvin S. Hausman, MD (Chief Scientific Officer & Co-Founder; immunologist, board-certified urological surgeon, former U.S. Public Health Service Surgeon at the NIH, pharmaceutical developer, and co-author of the 2026 Neuropsychopharmacology rat study) and Brad Listermann (Co-Founder & CEO), alongside scientific and veteran collaborators including Associate Professor Viviana Trezza, PhD (Roma Tre University), Lt. Col. Elton Johnson Jr., U.S. Army (Ret.), Dr. Louise Hecker, PhD, and Andrew Charrette, MSc (KGK Science).
02 · Category Two
Sub-perceptual dosing is intended to produce no noticeable psychedelic effects, using a small fraction of the 15 to 25 mg doses administered in supervised clinic sessions. Blinded single-dose research in healthy adults has evaluated low-dose oral psilocybin to characterize perceptual thresholds relative to placebo (Levy-Cooperman et al., 2026). Whether participants with mild PTSD can distinguish XYCO-02 from placebo during repeated dosing remains an open question.
In a 2026 Neuropsychopharmacology study (Ascone et al., DOI: 10.1038/s41386-026-02361-x) from Associate Professor Viviana Trezza's laboratory at Roma Tre University and the University of Milan, co-authored by Xycota CSO Dr. Marvin S. Hausman, MD, repeated low doses of psilocybin improved object-recognition memory in a Fragile X rat model (Fmr1-Δexon 8 rats). The improvement remained when researchers blocked 5-HT2A and disappeared when they blocked TrkB. Because that study was conducted in a genetic Fragile X rat model rather than a trauma model, whether this mechanism translates to clinical benefit in human PTSD has not yet been tested.
The low-dose, sub-perceptual regimen is formulated to minimize noticeable psychedelic effects. Whether participants with mild PTSD can distinguish XYCO-02 from placebo during repeated dosing remains an open question. In the planned 28-day study, researchers plan to measure PTSD symptoms (CAPS-5) and BDNF levels in blood; a change in blood BDNF alone would not establish brain repair or receptor engagement.
03 · Category Three
Not yet. The planned XYCO-02 study has not been approved by Health Canada and is not recruiting participants. When a study is authorized and opens for enrollment, details will be posted on ClinicalTrials.gov. Nothing on this website is an invitation to join a clinical study.
XYCO-02 is preclinical. Next step for XYCO-02: complete the Canadian Clinical Trial Application and submit with KGK Science. Xycota has not yet entered formal dialogue with Health Canada.
Our CRO partner KGK Science previously ran a Health Canada authorized study of low-dose, sub-perceptual oral psilocybin in adults with Fragile X Syndrome (NCT05832255), sponsored by Nova Mentis Life Science Corp. That study was open-label, single-arm, enrolled up to 10 participants, and is currently listed as suspended pending protocol revisions. Xycota does not own or control that dataset.
What it gives us is narrower than a dataset: the same CRO, prior cGMP low-dose capsule experience, and an existing Health Canada authorization precedent for sub-perceptual psilocybin dosing in an outpatient setting. Whether that supports a Phase 1 PK/PD waiver for XYCO-02 is a question for Health Canada, and we have not yet entered formal dialogue with the regulator.
Xycota does not directly handle bulk Schedule I material. Psilocybin and psilocin are Schedule I controlled substances in the United States and controlled substances in Canada; all formulation, cGMP analytical testing, storage, and trial supply logistics are planned to run through DEA and Health Canada licensed contract partners, including KGK Science in Canada.
No. All Xycota programs are investigational and preclinical. No Xycota product is approved by the FDA, Health Canada, or any other regulatory authority, and none is available for prescription or patient use.
Looking for immediate, non-clinical trauma support? Visit PTSD Resources →
04 · Category Four
The FDA grants Orphan Drug Designation to therapies for rare diseases affecting fewer than 200,000 people in the U.S. Xycota has filed an Orphan Drug Designation application for XYCO-01 in frontotemporal dementia. If granted, it provides incentives including potential seven-year U.S. market exclusivity upon approval, tax credits for qualified clinical testing, and a PDUFA application fee waiver.
Xycota maintains an email-verified, NDA-gated data room containing preclinical study reports, regulatory preparation files, and patent schedules for institutional investors, pharmaceutical/biotech partners, and clinical research institutions. Access is not available to retail or individual investors, and no securities are offered on this website.
Go to the Institutional Data Room → · Open the Investor Hub →